Pharmacological activators of PPARγ are being used as a treatment of obesity related disorders such as dyslipidaemia and type 2 diabetes, but questions remain open regarding the effects of PPARγ on traits related to the development of type 2 diabetes. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.